Csl Limited · ASX:CSL
Csl — Shareholder Meeting (October 2016)
12 slides from Csl's shareholder meeting presentation, Oct 12, 2016
Slide 1: Annual General Meeting
For personal use only Annual General Meeting 12 October 2016
Slide 2: Legal Notice: Forward looking statements
For personal use only Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include forward looking statements about CSL Limited and its related bodies corporate (CSL) financial results and estimates, business prospects and produ
Slide 3: FY16 Results
FY16 Results Revenue US$6.1 billion For personal use only • Underlying1 revenue up 8.2% @CC2 Guidance ~7% @CC EBIT US$1,438 million • Underlying EBIT up 7% @CC NPAT US$1,242 million • Reported NPAT down 10% • Underlying NPAT up 5.2% @CC Guidance ~5% @CC • NVS-IV NPAT ($116m) Guidance (~$90-120m) EPS
Slide 4: Group Sales
Group Sales FY16 For personal use only Sales US$5.9B Immunoglobulins North America Haemophilia Australia Europe Seqirus Specialty ROW Asia Albumin Broad portfolio of products and geographic reach 4
Slide 5: CSL Behring
CSL Behring US$M Product Sales up 10% @CC 6,000 For personal use only US$5,245m US$5,029m 5,000 4,000 Immunoglobulins Up 11% @CC 3,000 Haemophilia Up 4% @CC 2,000 Specialty Up 11% @CC 1,000 Albumin Up 12% @CC 0 Jun 15 Jun 16 Reported sales for the 12 month period 5
Slide 6: Seqirus
Seqirus US$M 800 For personal use only Seqirus US$652m Highlights 600 • FY16 includes 11 months from NVS-IV bioCSL NVS-IV1 • Mild 2015/16 northern hemisphere US$412m influenza season 400 Influenza • TIV portfolio in FY16 • In-license product fluctuation 200 Pharma & vaccines 0 Jun 15 Jun 16 Reported
Slide 7: Seqirus Update
Seqirus Update Operations For personal use only • Integration complete • Enhanced efficiency, sharing of best practices • New formulation facility in Liverpool Product launches • Recent US launch of Flucelvax Quadrivalent™ and Fluad™ • Full year impact from FY18 • Seqirus influenza vaccines 1st to m
Slide 8: R&D Update
R&D Update Idelvion® (rIX-FP) For personal use only • rIX-FP Phase III efficacy data supports 7-14 day dosing • Extension study supports dosing interval of up to 21 days for prophylaxis in appropriate patients • Adult and pediatric indications approved in Canada, US, EU, Switzerland, Australia and J
Slide 9: R&D Update
R&D Update Beriplex® (Prothrombin Complex Concentrate) For personal use only • Phase III study in Japan nearing completion • Orphan Drug Designation received in Japan in March 16 Berinert®/CSL830 (C1 Esterase Inhibitor) • CSL830 (subcut) pivotal Phase III study successfully completed • Berinert® app
Slide 10: CSL FY17 Guidance Reaffirmed
CSL FY17 Guidance Reaffirmed1 NPAT growth2 ~ 11% @ CC3 EBITDA growth2 ~14% @ CC For personal use only EPS growth to exceed NPAT growth Revenue expected to grow ~9% @ CC • Continued strong demand for plasma therapy products • Full year rCOAGs sales contribution • Seqirus fully participating in a norm
Slide 11: CSL Strategy for Profitable Growth
For personal use only CSL Strategy for Profitable Growth • CSL 112 – new treatment paradigm in ACS • Hizentra® expansion into neurology Future Growth • CSL 830 – HAE Pipeline • Pipeline antibodies • Targeted business development • Drive Seqirus business to profitability Seqirus • Successfully launch
Slide 12: Annual General Meeting Contact
For personal use only Annual General Meeting Contact - Mark Dehring Head of Investor Relations Telephone: +613 9389 3407 Email: mark.dehring@CSL.com.au